Primary hyperoxaluria

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
3 Commercial trials
Drug classes (ATC)
ATC code not specified 1
N Neurology/Psychiatry (ATC N) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
siRNA 1 substance
Phase III: 1 Phase II: 1 Phase I (First in Human): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial

Phase II

1 trial
  • Dicerna Pharmaceuticals Inc. Commercial
    NEDOSIRAN
    2024-512259-19-00 3 countries 2021 n=6 Orphan
    Recruiting

Phase I (First in Human)

1 trial
  • Arbor Biotechnologies Inc. Commercial
    MRNA-002, GRNA-001
    2024-518144-20-00 3 countries 2025 n=6
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Dicerna Pharmaceuticals Inc. Commercial 1 Phase II 1
Biocodex Commercial 1 Phase III 0
Arbor Biotechnologies Inc. Commercial 1 Phase I (First in Human) 1
New trials by year
2021
1
2025
1
← All indication landscapes